期刊
NATURE REVIEWS UROLOGY
卷 15, 期 10, 页码 595-597出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41585-018-0074-1
关键词
-
资金
- Genentech/Roche
- AstraZeneca
- Bristol-Myers Squibb (BMS)
- Seattle Genetics
- Merck
- Bayer
- EMD Serono
- Astellas
- Mirati Research
- Novartis
- BMS
The European Medicines Agency (EMA) and FDA have recently restricted the indications for first-line pembrolizumab and atezolizumab to patients with programmed cell death 1 ligand 1 (PD-L1)-high advanced urothelial carcinoma, a decision made following interim analyses from the ongoing Keynote-361 and IMvigor130 phase III trials. Questions remain on the magnitude of inferior survival and standardized implementation of PD-L1 testing.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据